Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
News|Articles|September 29, 2026
Heart Failure Society of America 2026 Preview: 6 Trials to Watch
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
Advertisement
Advertisement
The
Related to this article
The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.
Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).
Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).
Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.
Advertisement
Advertisement